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Abstract
Once-daily deferasirox dispersible tablets (DT) have a well-deﬁned safety and eﬃcacy proﬁle and,
compared with parenteral deferoxamine, provide greater patient adherence, satisfaction, and qual-
ity of life. However, barriers still exist to optimal adherence, including gastrointestinal tolerability
and palatability, leading to development of a new ﬁlm-coated tablet (FCT) formulation that can be
swallowed with a light meal, without the need to disperse into a suspension prior to consumption.
The randomized, open-label, phase II ECLIPSE study evaluated the safety of deferasirox DT and
FCT formulations over 24 weeks in chelation-naïve or pre-treated patients aged 10 years, with
transfusion-dependent thalassemia or IPSS-R very-low-, low-, or intermediate-risk myelodysplastic
syndromes. One hundred seventy-three patients were randomized 1:1 to DT (n 5 86) or FCT (n 5
87). Adverse events (overall), consistent with the known deferasirox safety proﬁle, were reported
in similar proportions of patients for each formulation (DT 89.5%; FCT 89.7%), with a lower fre-
quency of severe events observed in patients receiving FCT (19.5% vs. 25.6% DT). Laboratory
parameters (serum creatinine, creatinine clearance, alanine aminotransferase, aspartate amino-
transferase and urine protein/creatinine ratio) generally remained stable throughout the study.
Patient-reported outcomes showed greater adherence and satisfaction, better palatability and
fewer concerns with FCT than DT. Treatment compliance by pill count was higher with FCT
(92.9%) than with DT (85.3%). This analysis suggests deferasirox FCT oﬀers an improved formula-
tion with enhanced patient satisfaction, which may improve adherence, thereby reducing
frequency and severity of iron overload-related complications.
1 | INTRODUCTION
Transfusion and iron chelation therapy can be a lifelong requirement
for many patients with transfusion-dependent anemias. Compliance
with iron chelation therapy can inﬂuence the frequency and severity of
iron overload-related complications,1 with demonstrated improvement
in organ dysfunction and survival in patients compliant with iron chela-
tion therapy.2–6 The once-daily oral deferasirox dispersible tablet (DT)
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formulation (Exjade®), available since 2005, oﬀered an improved option
over parenteral deferoxamine (Desferal®), providing greater compli-
ance, patient satisfaction, and health-related quality of life.7,8 The eﬃ-
cacy and safety of deferasirox DT has been well-deﬁned through an
extensive clinical trial program in adult and pediatric patients with a
variety of anemias, including thalassemia, myelodysplastic syndromes
(MDS), sickle-cell disease, and other rare anemias,9–13 and has been
used in clinical practice worldwide for over a decade. Nonetheless, bar-
riers to optimal patient acceptance of treatment still exist with defera-
sirox DT, including palatability, the need to take the drug in a fasting
state (ie, not being able to take with food), and drug-related side
eﬀects, notably gastrointestinal (GI) tolerability.14 An improved ﬁlm-
coated tablet (FCT) formulation of deferasirox (US, Jadenu®; EU,
Exjade®)) has therefore been developed for oral administration.
Both deferasirox FCT and DT are once-daily, oral iron chelators
that are dosed based on body weight. The FCT contains the same
active substance, dose-adjusted to achieve comparable exposure to
that achieved with the DT,15 but excipients (lactose and sodium lauryl
sulfate) have been removed. As a result of increased bioavailability of
the FCT, doses required to achieve the same chelation eﬀect are 30%
lower than the DT.15 Deferasirox DT is taken according to labeling rec-
ommendations on an empty stomach, at least 30 min before the next
meal, and administration requires careful dispersion of the tablets in a
glass of water, orange juice, or apple juice, and has a chalky consistency.
Deferasirox FCT can be taken orally on an empty stomach or with a
light meal (<7% fat content and 250 calories), oﬀering a simpler and
more convenient mode of administration, and potentially improved GI
tolerability (due to a change in excipients and administration with food).
The phase II, randomized, open-label ECLIPSE study primarily eval-
uated the overall safety proﬁle, as well as pharmacokinetics (PK), and
patient-reported outcomes (PROs) of deferasirox FCT and DT formula-
tions in patients aged 10 years with transfusion-dependent thalasse-
mia (TDT) or very-low-, low-, or intermediate-risk MDS, requiring iron
chelation therapy.
2 | METHODS
2.1 | Key inclusion/exclusion criteria
Male and female patients aged 10 years with TDT or revised Interna-
tional Prognostic Scoring System (IPSS-R) very-low-, low-, or
intermediate-risk MDS were enrolled; patients could have been previ-
ously treated with iron chelators and required treatment with defera-
sirox DT doses 30 mg/kg/day (TDT) or 20 mg/kg/day (MDS) or be
chelation-naïve. Patients were also required to have a transfusion his-
tory of 20 packed red blood cell units, anticipated transfusion
requirements of 8 units/year during the study, and serum ferritin
>1000 ng/mL at screening. Key exclusion criteria were: creatinine
clearance (CrCl) below contraindication limit as per local label
(<60 mL/min or <40 mL/min); serum creatinine (SCr) >1.5 3 upper
limit of normal (ULN); alanine aminotransferase (ALT) >5 3 ULN
(unless liver iron concentration conﬁrmed as >10 mg Fe/g dry weight
6 months prior to screening); urine protein/creatinine ratio (UPCR)
>0.5 mg/mg; or impaired GI function.
2.2 | Study design
ECLIPSE was an open-label, randomized, multicenter, two-arm, phase II
study with the primary endpoint after 24 weeks of treatment (Support-
ing Information Figure S1). Randomization was stratiﬁed by underlying
disease and previous chelation treatment. In all chelation-naïve
patients, the starting deferasirox dose was 20 mg/kg/day with DT or
14 mg/kg/day with FCT. For previously treated patients, a washout
period of 5 days was required before randomization; all pre-treated
patients well managed on treatment with deferasirox DT, deferoxamine
or deferiprone were requested to start on a DT or FCT dose equivalent
to their pre-washout dose (eg, 20 mg/kg/day DT equivalent to 14 mg/
kg/day FCT equivalent to 75 mg/kg/day deferiprone equivalent to
40 mg/kg/day deferoxamine). Deferasirox DT was taken on an empty
stomach, at least 30 min before the next meal; FCT was taken (no later
than 12:00 pm) with or after a light meal. Dose adjustments to improve
treatment response based on serum ferritin levels and investigator’s
judgment were recommended every 4 weeks for chelation-naïve
patients and every 3 months for pre-treated patients, in increments of
5-10 mg/kg/day for DT or 3.5-7 mg/kg/day for FCT, up to a maximum
dose of 40 mg/kg/day for DT and 28 mg/kg/day for FCT. Dose adjust-
ments based on safety and dose reductions for patients unable to tol-
erate the protocol-speciﬁed dosing schedule were allowed at any time
during the study.
The study was conducted in accordance with Good Clinical Practice
guidelines and the Declaration of Helsinki, and was approved by inde-
pendent ethics committees at participating sites. Patients (or parents/
guardians) provided written, informed consent prior to enrollment.
2.3 | Outcomes
The primary endpoint was overall safety of deferasirox FCT and defera-
sirox DT formulations, measured by frequency and severity of adverse
events (AEs) and changes in laboratory values from baseline to 24
weeks. Secondary endpoints included the evaluation of both formula-
tions on selected GI AEs (diarrhea, constipation, nausea, vomiting, and
abdominal pain) during treatment, estimation of treatment compliance,
evaluation of both formulations on patient satisfaction, palatability, and
GI symptoms using PROs and evaluation of the PK of both formulations.
Safety was evaluated by monitoring and assessing AEs, changes in
laboratory parameters, and clinical observations from the start of study
treatment to 30 days after the last intake of study drug. Compliance to
treatment was evaluated by relative consumed tablet count (total con-
sumed tablet count/total prescribed tablet count) and patient-reported
treatment compliance using a daily compliance questionnaire. Patient
satisfaction, palatability of medicine, and GI symptoms were measured
for both formulations using PRO questionnaires (modiﬁed Satisfaction
with Iron Chelation Therapy [SICT] and palatability questionnaire) and
a GI symptoms diary. All PRO instruments used in this study (palatabil-
ity, GI symptom and modiﬁed SICT questionnaires) and estimation of
compliance (pill count) followed FDA Guidance to Industry for develop-
ment. Comprehensive qualitative, linguistic and psychometric validation
was performed within this trial; manuscripts on the qualitative valida-
tion and psychometric evaluation are in development. The modiﬁed
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SICT questionnaire used 5-point response scales to assess adherence
(six questions), satisfaction/preference (two questions), and concern
domains (three questions); higher scores in adherence and satisfaction/
preference domains indicated worse adherence, higher scores in con-
cern domain indicated fewer concerns. The palatability questionnaire
consisted of four items: taste and aftertaste of the medication (5-point
response scale: 15 very good; 55 very bad), whether the medication
was taken (ie, whether the patient vomited after swallowing medica-
tion or not) and how the patient perceived the amount of medication
to be taken (not enough, just enough, or too much). The GI symptom
diary consisted of six items: ﬁve items (pain in your belly, nausea, vom-
iting, constipation, diarrhea) rated on an 11-point scale (05 best,
105worst) and the sixth item, bowel movement frequency during the
past 24 h, using seven response options (0 = 0 [none], 151, 252,
353, 454, 555-10, and 6511). The modiﬁed SICT and palatabil-
ity questionnaires were completed at weeks 2 (considered as baseline),
3, 13, and end of treatment (within 7 days of the last dose). GI toler-
ability and treatment compliance diaries were completed daily. Serum
ferritin was measured at screening visits 1 and 2, and every 4 weeks
starting from week 5 until end of treatment.
Serial blood samples (pre-dose, 1, 2, 3, 4, 8, and 24 h post-dose)
were collected for a subset of patients to assess deferasirox PK during
treatment on the ﬁrst day of week 1 and week 3; pre-dose and 2-h
post-dose on the ﬁrst day of week 13 and week 21. For all other
patients, pre-dose and 2-h post-dose samples were obtained on the
ﬁrst day of week 3, week 13, and week 21.
2.4 | Statistical evaluations
Standard descriptive analyses were performed for both formulation
groups. No hypothesis was tested. The incidence of any AEs overall
and by severity was summarized by treatment using frequency counts,
percentages of patients, and 95% conﬁdence intervals (CIs) for percen-
tages obtained using Clopper–Pearson method. Laboratory data were
summarized using absolute change from baseline by treatment arm at
each post-baseline time window. The safety analysis set included all
patients who received at least one dose of the study drug and was
used for all safety evaluations. The PK analysis set consisted of all
patients who received at least one dose of study medication and had
at least one evaluable concentration measurement and was used for all
PK analyses. Serum ferritin data were considered as an exploratory,
non-safety outcome; absolute and relative change from baseline were
summarized by treatment arm at each post-baseline visit.
3 | RESULTS
In total, 173 patients were randomized 1:1 to DT (n586) or FCT
(n587; Table 1). Most patients had TDT (n570 in each arm) and 16
patients in each arm had MDS; most had received previous iron chela-
tion therapy (DT, n577 [89.5%]; FCT, n579 [90.8%]) and had
received deferasirox DT prior to the study (DT, n568 [79.1%]; FCT,
n571 [81.6%]; Table 1). Overall, 150 patients (86.7%) completed 24
weeks of treatment; patients discontinued treatment because of AEs
(n510), protocol deviation (n55), withdrawal of consent (n53),
patient guardian decision (n52), and other reasons (administrative
problems, death, and physician’s decision, n 5 1 each).
3.1 | Exposure to treatment and compliance
The mean actual deferasirox DT dose6 SD received during the 24-
week study was 27.567.73 mg/kg/day over a mean duration of
154.5644.67 days (median 168.0 days); the mean actual deferasirox
FCT dose6SD received was 20.865.44 mg/kg/day over a mean
duration of 163.2627.76 days (median 169.0 days; Table 2). More
patients receiving FCT were in the longest exposure category (12
weeks; DT 89.5%; FCT 96.6%) and highest mean actual dose category
(35 mg/kg/day DT/24.5 mg/kg/day FCT; DT n516, 18.6%; FCT
n527, 31.0%; Table 2). However, post-hoc analyses identiﬁed that 23
patients on FCT (26%) were started on a dose that was higher than
recommended in the protocol compared with eight patients (9.3%) on
DT (not recognized or reported by the investigators as dosing error).
Over 24 weeks, dose was interrupted at least once in 43 patients
(50.0%) receiving DT and 42 patients (48.3%) receiving FCT, primarily
because of dosing error (DT, n 5 17; FCT, n 5 20) as recorded by
investigators in the dosing administration record. Dose adjustments or
interruptions because of AEs were performed in 40 patients (46.5%) on
DT and 32 patients (36.8%) on FCT; the principal causes were UPCR
increased (DT, n 5 8 [9.3%]; FCT, n 5 10 [11.5%]) and diarrhea (DT, n
5 5 [5.8%]; FCT, n 5 6 [6.9%]). Other GI AEs of interest leading to
dose adjustments in patients on DT or FCT, respectively, were abdomi-
nal pain (n54 and n55), nausea (n53 in each arm), constipation
(n51 and n52), and vomiting (n52 in each arm). More dose adjust-
ments/interruptions were performed because of severe AEs in patients
on DT (n 5 12 [14.0%]) than FCT (n 5 5 [5.7%]), most frequently diar-
rhea (DT, n 5 2 [2.3%]; FCT, n 5 1 [1.1%]) and proteinuria (DT, n 5 1
[1.2%]; FCT, n 5 1 [1.1%]). Compliance with medication as assessed by
relative consumed tablet count was high: 85.3% (95% CI: 81.1, 89.5) in
the DT arm and 92.9% (95% CI: 88.8, 97.0) in the FCT arm.
3.2 | Safety of deferasirox DT and FCT
3.2.1 | Adverse events
Investigator-reported AEs regardless of relationship to deferasirox
were reported in 77 patients (89.5%) on DT and 78 patients (89.7%) on
FCT (Table 3). The most frequently reported AEs were diarrhea, nau-
sea, and abdominal pain (Table 3). Similar proportions of patients expe-
rienced one or more GI AE (deﬁned as abdominal pain, constipation,
diarrhea, nausea, or vomiting): 61.6% of patients (n 5 53; 95% CI 50.5,
71.9) receiving deferasirox DT and 58.6% (n 5 51; 95% CI 47.6, 69.1)
of those receiving FCT, with similar proportions in each treatment arm
experiencing diarrhea, nausea, and abdominal pain; 25.6% and 19.5%
of patients in the deferasirox DT and FCT groups, respectively, experi-
enced severe GI AEs (Table 3). Among patients with prior deferasirox
treatment, 41 (60.3%) receiving DT and 38 (53.5%) receiving FCT had
one or more GI AE; in patients without prior deferasirox treatment, 12
(66.7%) receiving DT and 13 (81.3%) receiving FCT had one or more GI
AE. Overall, the exposure-adjusted incidence of GI AEs was 137 per
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100 patient years in the FCT group and 153 per 100 patient years
in the DT group. GI hemorrhage and ulcers were seen in 3.5%
of patients receiving DT (hematochezia n 5 1 and rectal hemorrhage
n 5 2; Supporting Information); none were observed in patients receiv-
ing FCT.
AEs with a diﬀerence of 5% between treatment arms were
increased UPCR (DT, 12.8% [n 5 11]; FCT, 20.7% [n 5 18]), hematuria
(DT, 2.3% [n 5 2]; FCT 9.2% [n 5 8]), constipation (DT, 15.1% [n 5
13]; FCT, 8.0% [n 5 7]), headache (DT, 14.0% [n 5 12]; FCT, 5.7%
[n 5 5]), and inﬂuenza (DT, 5.8% [n 5 5]; FCT, 0.0% [n 5 0]). A post-
TABLE 2 Exposure to study drug by treatment
Exposure variable Deferasirox DT, N 5 86 Deferasirox FCT, N 5 87
Mean exposure6 SD, days 154.56 44.67 163.2627.76
Median exposure (range), days 168.0 (2-224) 169.0 (30-239)
Exposure category (weeks), n (%)
<4 5 (5.8) 0 (0.0)
4 to <12 4 (4.7) 3 (3.4)
12 77 (89.5) 84 (96.6)
Mean actual dose6 SD, mg/kg/day 27.5 (7.73) 20.8 (5.44)
Mean actual dose category, mg/kg/day 5 (5.8) 2 (2.3)
<15 DT/<10.5 FCT 28 (32.6) 26 (29.9)
15 to <25 DT/10.5 to <17.5 FCT 37 (43.0) 32 (36.8)
25 to <35 DT/17.5 to <24.5 FCT 16 (18.6) 27 (31.0)
35 DT/24.5 FCT
TABLE 1 Patient demographics, disease, and baseline characteristics by treatment
Variable Deferasirox DT, N 5 86 Deferasirox FCT, N 5 87 Total, N 5 173
Disease, n (%)
Transfusion-dependent thalassemia 70 (81.4) 70 (80.5) 140 (80.9)
MDS 16 (18.6) 16 (18.4) 32 (18.5)
Very-low-risk MDS 1 (1.2) 5 (5.7) 6 (3.5)
Low-risk MDS 8 (9.3) 10 (11.5) 18 (10.4)
Intermediate-risk MDS 7 (8.1) 1 (1.1) 8 (4.6)
Missing 0 (0.0) 1 (1.1) 1 (0.6)
Mean age6 SD, years 35.16 18.60 34.66 19.97 34.96 19.25
Median age (range), years 29.0 (11-81) 27.0 (12-81) 28.0 (11-81)
Male:female, n 39:47 46:41 85:88
Race, n (%)
Caucasian 61 (70.9) 62 (71.3) 123 (71.1)
Asian 20 (23.3) 16 (18.4) 36 (20.8)
Other 5 (5.8) 9 (10.3) 14 (8.1)
Mean time since diagnosis6 SD, years 22.36 11.95 19.96 11.30 21.16 11.66
Previous chelation, n (%)
Yes 77 (89.5) 79 (90.8) 156 (90.2)
No 9 (10.5) 8 (9.2) 17 (9.8)
Deferasirox prior to study, n (%)
Yes 68 (79.1) 71 (81.6) 139 (80.3)
No 18 (20.9) 16 (18.4) 34 (19.7)
Last chelation therapy received, n (%)
Deferasirox 57 (66.3) 60 (69.0) 117 (67.6)
Deferoxamine 7 (8.1) 6 (6.9) 13 (7.5)
Deferiprone 4 (4.7) 4 (4.6) 8 (4.6)
Combination therapy 9 (10.5) 9 (10.3) 18 (10.4)
Missing 9 (10.5) 8 (9.2) 17 (9.8)
Median serum ferritin (range), ng/mL 2485 (915-8250) 2983 (939-8250) -
SD, standard deviation.
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hoc evaluation of renal events demonstrated that the patients who
were started on a higher than protocol-recommended dose were more
likely to have renal events, which is consistent with the known safety
proﬁle of deferasirox (see below).
AEs with a suspected relationship to deferasirox were reported in
54 patients (62.8%) on DT and 41 patients (47.1%) on FCT, and were
predominantly (10%) diarrhea (DT 19.8%; FCT 13.8%), increased
UPCR (DT 10.5%; FCT 17.2%), abdominal pain (DT 16.3%; FCT 8.0%),
vomiting (DT 15.1%; FCT 4.6%), and nausea (DT 12.8%; FCT 9.2%). One
patient with MDS receiving FCT died during the study as a result of feb-
rile neutropenia; this was not suspected to be related to study drug.
Serious AEs (SAEs) were reported in 13 patients (15.1%) receiving
DT and 16 patients (18.4%) receiving FCT. Most SAEs were reported
for only one patient; SAEs of accidental overdose, diarrhea, and sepsis
were each reported for two patients receiving FCT. Five patients
receiving DT and three patients receiving FCT had SAEs suspected to
be related to study drug, most frequently GI disorders (DT, n 5 2; FCT,
n 5 1); events were considered severe in two patients receiving DT
(abdominal pain and dehydration/viral infection/renal impairment) and
in none receiving FCT.
Six patients in the deferasirox DT arm (7.0%) and ﬁve patients in
the deferasirox FCT arm (5.7%) had one or more AEs where study drug
was discontinued. GI-related disorders were the most common reason
for study drug discontinuation in patients receiving DT (n 5 4 [4.7%];
abdominal pain, abdominal pain upper, diarrhea, dysphagia), whereas
only one patient receiving FCT discontinued treatment because of a GI
event (Crohn’s disease).
3.2.2 | Laboratory parameters
Mean SCr increased initially but stabilized during the study, remained
within the normal range, and was similar with both formulations. In
most patients with normal values at baseline, SCr remained below ULN
during the study (DT 85.9% and FCT 90.8%); two consecutive SCr val-
ues >ULN and >33% increase from baseline were reported in four and
three patients in the DT and FCT groups, respectively. CrCl remained
greater than 60 mL/min during the study for most patients (DT 87.8%
and FCT 91.9%). Of 11 patients receiving DT and eight receiving FCT
who experienced at least one CrCl value <60 mL/min during the study,
four patients and one patient, respectively, had values below this
threshold at baseline.
Mean ALT and aspartate aminotransferase (AST) remained stable
throughout the study; baseline and end of treatment values were simi-
lar with both formulations. Similar proportions of patients (18%) in
both treatment arms who had ALT/AST values in the normal range at
baseline had at least one value >ULN during the study.
There were no signs of progressive UPCR increases from baseline
to end of treatment in either treatment group, although there was a
transient peak in mean UPCR (0.36 mg/mg [median 0.19, range 0.04-
1.98]) observed at week 9 in the FCT arm. Of patients with UPCR
<1.0 mg/mg at baseline, 7.2% of patients receiving DT and 16.1% of
patients receiving FCT experienced one value >1.0 mg/mg during the
course of the study.
The proportions of patients with post-baseline laboratory parame-
ters meeting the speciﬁed criteria for notable values were similar for
both formulations (Supporting Information Table S1).
3.2.3 | Post-hoc evaluation of patients with renal events
(renal adverse events and abnormal renal laboratory
parameters)
For the purpose of this detailed evaluation of patients with renal AEs
and abnormal renal laboratory parameters, a patient was classiﬁed as
experiencing a renal event if one of the following criteria was met: a
reported AE with the following preferred terms: renal impairment,
blood creatinine increased, blood creatinine abnormal, glomerular ﬁltra-
tion rate decreased, UPCR increased, proteinuria, UPCR abnormal,
urine albumin/creatinine ratio increased; SCr >33% above baseline and
>ULN in two consecutive values at least 7 days apart; recalculated
CrCl <40 mL/min; two consecutive UPCR values >0.5 mg/mg at least
48 hours apart. Fifty-nine patients met one or more of these criteria:
26 patients receiving DT and 33 patients receiving FCT. Evaluation of
the starting dose against the study protocol-recommended dose range
revealed that more patients receiving FCT were started on doses above
the protocol-recommended range (n523; 26.4%) than patients receiv-
ing DT (n58; 9.3%; Table 4).
Of all the patients who experienced renal events, 30.3% (n510/
33) of patients receiving FCT and 15.4% (n54/26) of patients receiv-
ing DT started on a higher than recommended dose. When patients
started at a correct starting dose, similar proportions of renal AEs were
seen in each arm: n520/60 patients (33.3%) receiving FCT and
n521/68 (30.9%) receiving DT.
TABLE 3 Most common AEs (overall and severe; >10% in any group) regardless of study drug relationship by preferred term and treatment
Deferasirox DT, N 5 86 Deferasirox FCT, N 5 87
AE All AEs n (%) Severe AEs n (%) All AEs n (%) Severe AEs n (%)
Total 77 (89.5) 22 (25.6) 78 (89.7) 17 (19.5)
Diarrhea 30 (34.9) 6 (7.0) 29 (33.3) 1 (1.1)
Nausea 23 (26.7) 2 (2.3) 24 (27.6) 1 (1.1)
Abdominal pain 23 (26.7) 4 (4.7) 23 (26.4) 2 (2.3)
Increased UPCR (>0.5) 11 (12.8) 2 (2.3) 18 (20.7) 0 (0.0)
Vomiting 19 (22.1) 1 (1.2) 15 (17.2) 0 (0.0)
Abdominal pain upper 6 (7.0) 1 (1.2) 10 (11.5) 0 (0.0)
Constipation 13 (15.1) 2 (2.3) 7 (8.0) 0 (0.0)
Headache 12 (14.0) 2 (2.3) 5 (5.7) 0 (0.0)
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3.3 | Evaluation of changes in serum ferritin levels
In patients receiving DT, median serum ferritin (range) decreased from
2485 (915-8250) ng/mL at baseline to 2064 (439-16 500) ng/mL at
end of treatment. In patients receiving FCT, median serum ferritin
(range) decreased from 2983 (939-8250) ng/mL to 2302 (443-8250)
ng/mL. The absolute change in median serum ferritin (range) in patients
receiving FCT was 2350 (24440 to 3572) ng/mL and in those receiv-
ing DT was285.5 (22146 to 8250) ng/mL; these correspond to a rela-
tive change of 214.0% with FCT and 24.1% with DT.
3.4 | Clinical PK
Deferasirox pre-dose concentrations (Ctrough) at steady state were similar
to both DT and FCT formulations throughout the study. Geometric
mean of Ctrough (dose-adjusted) for DT and FCT were 25.2 mmol/L versus
23.4 mmol/L at week 3, 26.1 mmol/L versus 23.6 mmol/L at week 13, and
32.3 mmol/L versus 31.4 mmol/L at week 21, respectively.
Geometric mean deferasirox concentrations 2 h post-dose at
steady state were slightly higher with FCT than DT at week 3 (80.9 vs.
69.4 mmol/L), week 13 (85.5 vs. 67.8 mmol/L), and week 21 (92.7 vs.
71.8 mmol/L).
PK variability shown as coeﬃcient of variation of geometric mean
was smaller with FCT than DT. Results were similar with or without
dose normalization, which suggest that overall exposure to deferasirox
was similar for both formulations, with slightly higher post-dose con-
centrations with FCT. PK results observed in this study were consistent
with data previously obtained in healthy volunteers (data on ﬁle).
3.5 | Patient-reported outcomes
Completion rates for PRO instruments were: 80% for the PRO
questionnaire at the beginning of the study, reducing to 70% by
month 24; 60% reducing to 30% for the compliance diary; and
70% reducing to 35% for the GI symptom diary. Throughout the
24-week study period, for modiﬁed SICT, patients receiving FCT
reported consistently greater adherence (attributable to: ﬁnding it eas-
ier to remember to take medication, thinking less often about stopping
medication, following instructions from the doctor more closely, ﬁnding
medication easier to take, being less bothered by the time taken to pre-
pare medication and the waiting time before eating), greater satisfac-
tion/preference (in general and also with administration of medicine),
and consistently fewer concerns (attributable to: being less worried
about not swallowing enough medication, experiencing fewer limita-
tions in daily activities, feeling less concerned about side eﬀects) than
patients receiving DT (Figure 1A-C). The diﬀerence in score between
the two formulations was >1 point (minimal important diﬀerence
[MID]) for all three domains at every visit, and no overlapping CIs at
almost every timepoint, indicating a clinically meaningful diﬀerence
between formulations. Patients receiving FCT reported consistently
higher satisfaction on palatability scores, reporting no taste or after-
taste and that they were able to swallow the full amount of medicine
with the right amount of liquid compared with patients receiving DT
(Figure 1D). The overall GI symptom scores were low for both formula-
tions, indicating patients experienced very little trouble/concern associ-
ated with GI symptoms (Figure 1E). Results favored FCT with patients
reporting near-perfect scores for all three modiﬁed SICT domains and
palatability.
4 | DISCUSSION
The ECLIPSE study evaluated safety, PK, and PRO of the original defer-
asirox DT formulation and the new dose-adjusted FCT formulation,
which contains the same active substance and can be swallowed with-
out the need to disperse into a suspension, in patients with lower-risk
TABLE 4 Evaluation of starting dose of study drug for all patients and patients with renal events
Starting dosea All patients, n (%)
All patients, n (%) Deferasirox DT (N5 86) Deferasirox FCT (N5 87)
Below protocol-recommended dose 10 (11.6) 4 (4.6)
Protocol-recommended dose 68 (79.1) 60 (69.0)
Above protocol-recommended dose 8 (9.3) 23 (26.4)
Patients with renal event, n/N (%) DT (n526) FCT (n533)
Below protocol-recommended dose 1/10 (10.0) 3/4 (75.0)
Protocol-recommended dose 21/68 (30.9) 20/60 (33.3)
Above protocol-recommended dose 4/8 (50.0) 10/23 (43.5)
Patients without renal events, n/N (%) DT (n560) FCT (n554)
Below protocol-recommended dose 9/10 (90.0) 1/4 (25.0)
Protocol-recommended dose 47/68 (69.1) 40/60 (66.7)
Above protocol-recommended dose 4/8 (50.0) 13/23 (56.5)
aChelation-naïve patients: starting dose required to be within6 15% of 14 and 20 mg/kg/day doses for FCT and DT, respectively. Prior chelated
patients: Starting dose required to be within 15% of an equivalent FCT or DT dose corresponding to their pre-washout dose. The maximum starting
dose allowed was 115% of 28 and 115% of 40 mg/kg/day doses for FCT and DT, respectively.
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FIGURE 1 Mean domain scores for patient-reported outcomes (adherence, satisfaction/preference, and concern) (A-C), mean palatability
score (D), and mean gastrointestinal symptom scores (E). For adherence (A; scale 6-30), satisfaction/preference (B; scale 2-10), and GI symp-
toms (E; scale 0-50), higher scores indicate worse outcomes/symptoms. For concern (C; scale 3-15) and palatability (D; scale 0-11), higher
scores indicate fewer concerns and better palatability. A-D, baseline was deﬁned as week 2 assessment. If missing, then the week 3 assess-
ment was considered baseline; E, baseline was deﬁned as week 1 score. If missing, then the week 2 score was considered baseline. BL,
baseline.
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MDS and thalassemia. The results demonstrate similar safety proﬁles
for FCT and DT, both consistent with the known proﬁle of deferasirox,
with no new safety signal identiﬁed. The exposure-adjusted GI AE rate
and incidence of severe GI AEs provide evidence for acceptable GI tol-
erability. Combined with the simpler and more convenient mode of
administration of the FCT, these factors likely contributed to the
observations that more patients receiving FCT remained on treatment
for at least 12 weeks and were more compliant with treatment.
Although the study was only 6 months, a reduction in serum ferritin
of 14% and 4.1% was observed with FCT and DT, respectively. In
addition to greater compliance with treatment, it was found that a
larger proportion of patients in the FCT group received a higher than
recommended dose, which could have contributed to the observed
serum ferritin reduction. Further analyses are warranted to speciﬁ-
cally determine the eﬀects of deferasirox FCT on the serum ferritin
levels.
The PRO analyses, using instruments validated within this trial,
show a beneﬁt in favor of deferasirox FCT in all domains for the modi-
ﬁed SICT, including greater adherence, greater satisfaction, fewer con-
cerns, and better palatability with respect to taste and ability to
consume medicine; patients receiving FCT achieved clinically meaning-
ful and important diﬀerences compared with patients receiving DT for
all domains. Overall, all patients were satisﬁed with their medicine dur-
ing the study period; satisfaction scores were higher with deferasirox
FCT compared with DT at all visits.
GI disturbances are often reported during clinical evaluation of
deferasirox, usually mild-to-moderate and occurring early in the course
of treatment.16 As deferasirox FCT can be taken with a light meal and
also lacks the excipients lactose and sodium lauryl sulfate, both found
in the original DT formulation and possibly implicated in GI AEs, it was
expected that deferasirox FCT would show improved GI tolerability.
Although similar numbers of patients in each arm experienced one or
more GI AEs or received dose adjustments as a result of GI AEs, 25.6%
and 19.5% of patients in the deferasirox DT and FCT groups, respec-
tively, experienced severe GI AEs (including diarrhea, nausea, and
abdominal pain) and four patients (DT) and one patient (FCT) discontin-
ued treatment because of GI AEs. These results were reﬂected in the
PROs: patients receiving FCT reported little or no concern with GI
symptoms. Taken together, these results suggest that the GI
tolerability proﬁle may be improved with FCT compared with DT,
which could be because of the change in excipients and/or the ability
to take the medicine with a light meal. Further insight should be gained
once longer-term data are available.
In the current study, more patients receiving FCT experienced
renal AEs or abnormal renal parameters than those receiving DT,
although the number of patients with renal laboratory values in the
notable/extended ranges were either similar or lower in the FCT arm.
Renal laboratory changes and AEs are well characterized with defera-
sirox therapy and are generally mild, non-progressive, and reversible.17
As such, the observed imbalance in reported renal events between the
two treatment arms are likely attributed to a larger proportion of
patients in the FCT group receiving a higher than recommended dose,
as well as non-adherence to protocol-recommended dose modiﬁca-
tions and (renal) exclusion criteria during the relatively short duration
of the study. Longer-term follow-up of patients is warranted to conﬁrm
whether the FCT has any notable eﬀect on the occurrence of renal
events.
This study demonstrates that to achieve optimal treatment bene-
ﬁts from iron chelation with deferasirox, it is highly recommended to
manage and monitor patients in accordance with the product label. In
particular, the results highlight the importance of ensuring that patients
start treatment on the correct dose. Care should be taken when
switching patients to FCT to ensure a dose equivalent to their previous
iron chelation treatment is administered (eg, FCT doses are 30% lower
than DT doses, conversion factor 1.43). Evaluation of PK data in this
study conﬁrmed that patients treated with dose-adjusted FCT achieved
comparable exposure to that achieved with DT, with similar pre-dose
deferasirox levels and slightly higher 2-h post-dose levels observed
with FCT.
Patient survival can be aﬀected by compliance with medical
treatment, particularly iron chelation, which in turn can be inﬂuenced
by a number of factors, including patient satisfaction with/prefer-
ence for their medication.3,18 Patient satisfaction rates for defera-
sirox DT have been reported to be as high as 90%,19 yet studies
have shown that most patients dislike the mode of administration for
deferasirox DT and would prefer to be able to take their medication
with food.20 Barriers such as these likely contribute to a reduced
patient-reported adherence to deferasirox DT of 67-86%.21 To
improve patient satisfaction and palatability of medication, and
thereby adherence, the new FCT was developed to be taken with or
after a light meal and was manufactured without sodium lauryl sul-
fate. In this study, validated methods indicated that compliance was
higher with deferasirox FCT than with DT, with patients reporting
better palatability, greater adherence, and fewer concerns with
deferasirox FCT than with DT. The results show that patient satisfac-
tion and adherence is improved with FCT; long-term studies will be
valuable to conﬁrm that this translates into improved clinical out-
comes, with fewer iron overload-related complications and improved
survival.
In this study in patients with TDT or IPSS-R very-low-, low-, or
intermediate-risk MDS, FCT demonstrated a short-term safety proﬁle
consistent with the known deferasirox DT proﬁle. Patients receiving
FCT had better treatment compliance and experienced a reduction in
serum ferritin, which are promising outcomes for continuing treat-
ment, though longer-term evaluation of the FCT is still required to
support these results. This study suggests that deferasirox FCT oﬀers
patients an improved formulation that does not require administration
in a fasting state, has better palatability, and minimal concerns associ-
ated with GI tolerability. However, it appears that in some patients,
there were errors in converting the dose from the DT to the FCT
and clinicians are advised to closely follow the recommendations in
the prescribing information. Overall, patient satisfaction was
enhanced with deferasirox FCT, which may improve adherence,
thereby reducing frequency and severity of iron overload-related
complications.
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